##Phase II PROMIX trial (https://clinicaltrials.gov/ct2/show/NCT00957125)

Prior Publications

(1)Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial. Int J Cancer 2018 Feb 1;142(3):618-628. PMID: 28940389.

(2)An HIF-1Î±/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression. Cancer Cell 2017 Nov 13;32(5):669-683.e5. PMID: 29136509.

(3)Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing. Cell 2018 May 3;173(4):879-893.e13. PMID: 29681456.

(4)Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer. Oncoimmunology 2018;7(9):e1466017. PMID: 30228933.
